Project Grant F31DK146643
- Federal Project Grant Award Summary Yale University received a $249,999 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective July 1, 2026 through June 30, 2027. The award funds research to elucidate the mechanisms of transcriptional dysregulation in myelodysplastic syndromes (MDS) caused by SF3B1 mutations, a splicing factor implicated in over half of all MDS...
- Federal Grant Award Summary Yale University received a $133,333 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 15, 2025, with completion targeted for August 31, 2026. The award funds research aimed at correcting the myeloid bias of aged hematopoietic stem and progenitor cells (HSPCs) by preventing linker histone turnover,...
- Federal Grant Award Summary Yale University received a $3.23 million Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 1, 2025, through August 31, 2029. The award supports investigator-initiated biomedical research focused on understanding the role of neutrophils in the pathogenesis of cholangiopathies—a group of bile duct diseases...
- Federal Grant Award Summary Yale University received a $802,715 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective March 1, 2026, with a completion date of January 31, 2030. The project investigates pathogen-induced biliary inflammation in the pathogenesis of sclerosing cholangiopathies, particularly primary sclerosing cholangitis (PSC), a chronic...
- Federal Project Grant Award Summary The University of California, San Francisco (UCSF) was awarded $3,140,632 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for a four-year project period from September 1, 2025, through August 31, 2029. This Project Grant supports fundamental biomedical research focused on elucidating the mechanisms of human endocrine lineage commitment...
- Project Grant Award Summary The University of California, San Francisco received a $191,700 Project Grant awarded on January 11, 2026, by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award, with a completion date of August 31, 2028, supports fundamental biomedical research investigating the mechanisms underlying autosomal-dominant polycystic kidney disease (ADPKD) and...
- Federal Project Grant Award Summary Indiana University Indianapolis received a $104,433 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded January 1, 2026, with completion expected July 31, 2028. The funded research investigates the interaction between parathyroid hormone (PTH) and muscle-derived irisin (produced via FNDC5) in chronic kidney...
- Federal Grant Award Summary Boston University Medical Campus received a $100,228 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective February 1, 2027, with a completion date of June 30, 2029. The award funds research to develop and evaluate induced pluripotent stem cell (iPSC)-derived endothelial cell therapy as a therapeutic intervention to...
- Federal Project Grant Award Summary Baylor College of Medicine received a $100,228 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective February 1, 2027, with completion targeted for June 30, 2027. The award funds biomedical research investigating the roles and dynamics of the endoplasmic reticulum (ER) during paligenosis and metaplasia formation in...
- Summary of Federal Project Grant Award Icahn School of Medicine at Mount Sinai received a $253,500 Project Grant award dated August 21, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research project, titled "Longitudinal Single Cell Responses in Human Islet Organoids to Beta Cell Regenerative Drugs," will be conducted through June 30, 2027, and...
Yale University received a $106,228 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 30, 2026, with completion targeted for May 31, 2030. The award supports research to develop functional parathyroid-like cells derived from human induced pluripotent stem cells (iPSCs) through directed differentiation protocols. This research addresses hypoparathyroidism, a debilitating condition resulting from parathyroid tissue loss or dysfunction—commonly occurring after thyroid or neck surgery—for which current treatments provide only suboptimal calcium regulation compared to native tissue. The project will deliver a validated stem cell differentiation protocol that generates parathyroid cells capable of calcium-responsive parathyroid hormone secretion. Research activities include developing and testing differentiation strategies guided by developmental biology principles, employing single-cell RNA sequencing analysis of developing parathyroids to identify specification pathways, and assessing lineage fidelity through expression of parathyroid-specific markers (GCM2, PTH, CASR) and functional calcium responsiveness in vitro. The work integrates small molecule signaling pathway modulation and transcriptional programming to advance toward a potentially curative stem cell-derived therapeutic alternative to current chronic supplementation and hormone replacement therapies for hypoparathyroidism.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 4/28/26 | ||
| Not listed | $53.1k | 4/28/26 | ||
| Not listed | $53.1k | 4/28/26 |